CMS recently determined that the evi- dence is sufficient to cover ambulatory BP monitoring for the diagnosis of hypertension in Medicare beneficiaries with suspected white coat or masked hypertension.11,12 Annals of Internal Medicine also published an In the Clinic section for screening, prevention, diagnosis, and treatment of hypertension, citing the 2017 Hypertension Clinical Practice Guidelines.13 The writing committee was also interested in trans- lating some of the 2017 Hypertension Clinical Practice Guidelines recommendations for systematic strategies that support the consistent and accurate diagnosis and treatment of populations of patients with HBP.4 In its deliberations on this challenge, the writing committee felt that it would be cumbersome and challenging to collect data at the patient and individual clinician levels, thereby limiting the use and utility of measures speci- fied at these levels. With these potential constraints in mind, the writing committee created 10 new structural quality measures designed to evaluate the capability and capacity of various levels of the US healthcare system to implement 2017 Hypertension Clinical Practice Guide- lines recommended strategies, such as standardized BP measurement protocols, electronic health record surveil- lance, telehealth, team-based care, a single plan of care, and performance measurement.4 These new measures are intended for qualitative evaluation of process and infrastructure for these strategies at the care delivery unit (CDU) level (including solo/small physician offices, group practices, health systems, public health sites, accountable care organizations, and clinically integrated networks). Summaries for these measures are displayed in Tables 4 and 5, which provide information on each measure. Tables 4 and 5 also list each of the new measures and which ACC/AHA classes of HBP are addressed for each. 